



## Sanofi Genzyme reaffirms its commitment to support patients with rare diseases in India

- 20 years of providing free treatment to patients with rare disorders in India
- Partners with patient groups to raise awareness about rare diseases in India

**Mumbai – February 26, 2018** – Sanofi Genzyme, the specialty care global business unit of Sanofi, reaffirms its commitment to go the extra mile for patients with rare diseases in India. It has partnered with patient support groups in major cities across the country on the occasion of Rare Disease Day (that falls on 28 February 2018) to raise awareness and sensitize the public about rare diseases in India.

**N. Rajaram, Managing Director, Sanofi India, said,** *“Given the low burden of rare diseases in the country, these patients are often ‘invisible’ to the public health system. They incur very high diagnostic and treatment costs and do not receive the guidance and support they need. Sanofi Genzyme is committed to working with the community of patients, physicians and researchers to enable effective diagnosis, focused education and sustainable access to treatment.”*

Sanofi Genzyme is recognized as one of the industry's most generous in-kind givers, and 2018 marks the 20<sup>th</sup> year of Sanofi Genzyme's humanitarian program in India. Through the charitable access program, known as INCAP (**IN**dia **Ch**aritable **A**ccess **P**rogram), Sanofi Genzyme is currently providing free Enzyme Replacement Therapy to patients with Lysosomal Storage Disorders (LSDs) in India.

INCAP has grown significantly since its inception in 1999 and is widely appreciated for its altruistic efforts to support the LSD community by providing therapy to patients who lack sufficient financial resources to avail of these therapies. Today, over a hundred patients are benefitting from the enzyme replacement therapies being provided under INCAP, for rare diseases like Gaucher disease, Pompe disease, Fabry disease, and MPS I (Mucopolysaccharidoses) disease.

Sanofi Genzyme in India is focused on treatment for rare diseases, multiple sclerosis and immunology.

### About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare.

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

## About Rare Diseases Day

Observed every year on the last day of February, Rare Disease Day is an international awareness campaign established by the European Organisation for Rare Diseases (EURORDIS) in 2008. It is globally supported by hundreds of patient organizations. This day provides an opportunity to bring to the fore the impact that these debilitating diseases have on patients and their families.

## Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

---

## Contacts:

### Media Relations

Aparna Thomas

Tel.: +91 22 2803 2169

[aparna.thomas@sanofi.com](mailto:aparna.thomas@sanofi.com)

Sohil Bahamania

Tel: +91 22 2803 2446

[sohil.bahamania@sanofi.com](mailto:sohil.bahamania@sanofi.com)